Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s traded shares stood at 0.44 million during the latest session, with the company’s beta value hitting 0.93. At the last check today, the stock’s price was $11.15, to imply a decrease of -5.51% or -$0.65 in intraday trading. The ARWR share’s 52-week high remains $30.41, putting it -172.74% down since that peak but still an impressive 14.17% since price per share fell to its 52-week low of $9.57. The company has a valuation of $1.53B, with an average of 2.37 million shares in intraday trading volume over the past 10 days and average of 2.04 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Arrowhead Pharmaceuticals Inc (ARWR), translating to a mean rating of 1.67. Of 9 analyst(s) looking at the stock, 0 analyst(s) give ARWR a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.46.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) trade information
After registering a -5.51% downside in the latest session, Arrowhead Pharmaceuticals Inc (ARWR) has traded red over the past five days. The 5-day price performance for the stock is -7.55%, and -29.30% over 30 days. With these gigs, the year-to-date price performance is -40.69%. Short interest in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) saw shorts transact 10.44 million shares and set a 7.18 days time to cover.
The extremes give us $24 and $29.97 for target low and target high price respectively. As such, ARWR has been trading -168.79% off suggested target high and -115.25% from its likely low.
Arrowhead Pharmaceuticals Inc (ARWR) estimates and forecasts
The rating firms project that company’s revenue will grow 8,932.46% compared to the previous financial year.
Revenue forecast for the current quarter as set by 11 analysts is 116.27M. Meanwhile, for the current quarter, a total of 11 analyst(s) estimate revenue growth to 51.27M.
ARWR Dividends
Arrowhead Pharmaceuticals Inc has its next earnings report out on 2025-Feb-09. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s Major holders
Arrowhead Pharmaceuticals Inc insiders hold 13.19% of total outstanding shares, with institutional holders owning 74.66% of the shares at 86.01% float percentage. In total, 74.66% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 15.68 million shares (or 12.6275% of shares), all amounting to roughly $407.61 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 12.21 million shares, or about 9.9072% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $317.44 million.
We also have iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Arrowhead Pharmaceuticals Inc (ARWR) shares. Going by data provided on Feb 28, 2025 , iShares Trust-iShares Core S&P Small-Cap ETF holds roughly 7.92 shares. This is just over 5.77% of the total shares, with a market valuation of $87.48 million. Data from the same date shows that the other fund manager holds a little less at 3.66, or 2.67% of the shares, all valued at about 40.44 million.
